About Binder Biotechnology

About company

Binder Bio Group (hereinafter referred to as “Binder Bio”, BindeBio) was established in 2015 and Shenzhen Binder Biotechnology Co., Ltd. is the holding company. Binder Biotech has received strong support from the Shenzhen Municipal Government and has established extensive and in-depth cooperation with the Chinese Academy of Sciences and a number of authoritative hospitals across the country. It is a biotechnology group company that focuses on the treatment of cancer with immune cells. Based on the internationally leading CAR-T and TCR-T immune cell technologies, Binder Biotech is committed to the development and marketing of immunotherapy.